Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07160959

Physical Exercise to Prevent Mild-cognitive Impairment in Patients With Kidney Disfunctions

This research project focuses on improving memory and thinking (cognitive function) in people with advanced chronic kidney disease (CKD), a condition that affects about 10% of adults and is often linked to cognitive problems. The study includes a clinical trial where patients will either receive standard care or follow a home-based exercise program involving walking and strength training, to see if regular physical activity can improve brain function. It also includes a large-scale analysis of data from the UK Biobank to explore blood and genetic markers, brain imaging, and lifestyle factors linked to cognitive health. The ultimate aim is to find effective, easy-to-implement strategies and early warning signs that could lead to better treatment and quality of life for people living with CKD.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Chronic Kidney Disease (stages 4 and 5) Behavior Chronic Disease Cognition Disorders Cognitive Dysfunction Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Mental Disorders Mild Cognitive Impairment (MCI) Motor Activity Neurocognitive Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Assistance Publique - Hôpitaux de Paris (AP-HP), Division of Geriatry, Paris, France

Loading trial locations.

About this study

The project aims to test the impact of exercise programs on cognitive function in stage G 4-5 CKD and dialysis patients with MCI in a randomised clinical trial. A structured physical exercise program (walking exercise) effectively improved physical performance and quality of life in dialysis patients in a previous trial by us (see reference 6 by the investigators of this proposal). We will combine resistance and walking exercise in the active arm of the trial. In parallel with this trial, the project aims to test the cross-sectional and longitudinal relationship between physical activity (PAA) and the genetic and circulatory biomarkers of cognitive function and brain MRI in CKD patients and individuals without CKD in the UK Biobank.

Randomised clinical trial This trial will test a structured combined physical exercise program based on home-based aerobic (walking) exercise and resistance exercise maintained for 26 weeks on cognitive function in predialysis patients with advanced CKD (stages 4-5) and dialysis patients with MCI compared to the usual care (control group). In the two study arms, nutritional guidelines by KDIGO will be implemented, and nutrient intake will be periodically assessed. For this purpose, an App for CKD patients, including dietary advice and registering nutrients, will be adapted to the languages of centres in participating countries. Furthermore, body composition will be assessed during the study visits using validated bio-impedance spectroscopy instruments. Two-thirds of enrolees will be predialysis CKD patients and one-third dialysis patients (haemodialysis or peritoneal dialysis patients). Partners or caregivers to assist patients in the trial's exercise arm are requested explicitly for inclusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • CKD at KDOQI stage 4-5
  • concomitant MCI (MOCA - MMSE (17 < MoCA < 26) or (16 < MMSE < 24)

Exclusion criteria

  • Absolute contraindication to exercise training (e.g. unstable angina, major amputation, severe heart failure, etc.)
  • Known life expectancy < 6-month
  • Uncorrected anemia (Hb <9 g/dl)
  • Non-provision of informed consent

Treatment and study plan

Exercise

Behavioral

Patients will undergo a home-based low-intensity interval multi component exercise program including aerobic and strengthening exercise

Control (Standard treatment)

Other

Patients will be treated with standard therapy based on their CKD stage

Primary outcomes

  1. Cognitive function

    Time frame: Baseline; End of program (6-month); Follow up (12-month; 24-month)

    Cognitive function using the Alzheimer Disease Assessment Scale Cognitive 11 (ADAS-Cog-11)

Secondary outcomes

  1. Magnetic Resonance Imaging (MRI)

    Time frame: Baseline and 6 months

    Blood Oxygenation Level-Dependent (BOLD) Signal will be collected through functional MRI executed according to the published standards

  2. 6-minute walking test

    Time frame: Baseline; End of program (6-month); Follow up (12-month; 24-month)

    The patients will be instructed to walk back and forth on a 20-meter corridor aiming at covering as much distance as possible. The total distance covered (6MWD) will be measured in meters

  3. Quality of life assessment

    Time frame: Baseline; end of the program (6-month); Follow up (12-month; 24-month)

    Quality of life will be assessed by the short-form 36 (SF-36) questionnaire This is a generic questionnaire that contains 36 questions referring to 8 specific domains related to patient health over the previous 4 weeks

  4. Lower limbs strength assessment

    Time frame: Baseline; end of the program (6-month); Follow up (12-month; 24-month)

    Lower limbs strength assessed by the 5-time sit-to-stand test Patients will raise up from a standard height chair with their arms folded across the chest five times as quickly as possible. The total time elapsed for completing the five repetitions is recorded in seconds

  5. Handgrip strength

    Time frame: Baseline; End of program (6-month); Follow up (12-month; 24-month)

    Handgrip strength will be measured by a standard dynamometer. Peak value in kg for both arms will be collected

  6. Body mass index assessment

    Time frame: Baseline, end of the program (6-month); follow up (12-month; 24-month)

    Body mass index Body composition will be assessed with direct measures of height and weight. Body mass index will be calculated as the ratio between weight (in kg) and the squared height (in meters)

  7. Safety and tolerability

    Time frame: End of treatment (6-month)

    Number of participants with treatment-related adverse events as assessed by the CTCAE version 4.0

  8. Long-term survival rate assessment

    Time frame: Baseline, end of treatment (6-month); follow up (12-month); follow up (18-month); Follow up (24-month); Follow up (36-month)

    Long-term survival rate All-cause mortality of the enrolled patients will be checked from the regional's datasets. In case of positive findings, the days elapsed from enrollment to the event will be recorded for additional analyses, as well as the reasons and the diagnoses.

  9. Long-term hospitalizations assessment

    Time frame: Baseline, end of treatment (6-month); follow up (12-month); follow up (18-month); Follow up (24-month); Follow up (36-month)

    Long-term hospitalizations All-cause hospitalization will be checked from the regional's datasets. In case of positive findings, the days elapsed from enrollment to the event will be recorded for additional analyses, as well as the reasons and the diagnoses.

Study contacts

Contact information is provided by the study sponsor or research team.

Crmine Zoccali

CONTACT

[email protected]

+393407354062

Sponsors and collaborators

Lead sponsor

Biogem s.c.ar.l.

Other

Registry information

Official study title

Physical Exercise to Prevent Mild-cognitive Impairment Progression in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients

Acronym: Exprecoimp-CKD

Important dates

Study start
2026
Primary completion
2028
Study completion
2030
First posted
Sep 8, 2025
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.